InspireMD (NSPR) Q2 FY26 earnings call

InspireMD navigated a challenging quarter marked by a voluntary recall of its CGuard Prime 135 system, which significantly impacted reported financials. Despite this, the company demonstrated resilience with strong international growth and made meaningful progress on multiple regulatory fronts, including advancing its TCAR and CAS platforms towards anticipated Q4 FDA approvals. Management has also taken decisive actions to streamline its cost structure and organization, positioning the company for a strategic U.S. market re-entry and long-term growth.